News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
84,316 Results
Type
Article (9771)
Company Profile (53)
Press Release (74492)
Multimedia
Podcasts (8)
Webinars (2)
Section
Business (22198)
Career Advice (111)
Deals (3146)
Drug Delivery (10)
Drug Development (12349)
Employer Resources (17)
FDA (1785)
Job Trends (2288)
News (38464)
Policy (3287)
Tag
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
Academia (667)
Accelerated approval (9)
Adcomms (5)
Allergies (10)
Alliances (7069)
ALS (39)
Alzheimer's disease (314)
Antibody-drug conjugate (ADC) (22)
Approvals (1830)
Artificial intelligence (81)
Autoimmune disease (14)
Automation (5)
Bankruptcy (15)
Best Places to Work (2167)
BIOSECURE Act (3)
Biosimilars (9)
Biotechnology (46)
Bladder cancer (21)
Brain cancer (21)
Breast cancer (73)
Cancer (700)
Cardiovascular disease (93)
Career advice (98)
Career pathing (2)
CAR-T (62)
CDC (1)
Celiac Disease (1)
Cell therapy (188)
Clinical research (9967)
Collaboration (350)
Compensation (178)
Complete response letters (15)
COVID-19 (392)
CRISPR (55)
C-suite (135)
Cystic fibrosis (90)
Data (1235)
Denatured (1)
Depression (9)
Diabetes (62)
Diagnostics (1567)
Digital health (4)
Diversity (1)
Diversity, equity & inclusion (9)
Drug discovery (50)
Drug pricing (6)
Duchenne muscular dystrophy (111)
Earnings (7189)
Editorial (9)
Employer branding (3)
Employer resources (16)
Events (12889)
Executive appointments (120)
FDA (2307)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (7)
Frontotemporal dementia (11)
Funding (222)
Gene editing (134)
Generative AI (4)
Gene therapy (321)
GLP-1 (101)
Government (542)
Grass and pollen (1)
Guidances (58)
Healthcare (2418)
HIV (10)
Huntington's disease (21)
IgA nephropathy (15)
Immunology and inflammation (26)
Immuno-oncology (4)
Indications (14)
Infectious disease (420)
Inflammatory bowel disease (33)
Inflation Reduction Act (2)
Influenza (6)
Intellectual property (27)
Interviews (14)
IPO (1633)
IRA (2)
Job creations (282)
Job search strategy (92)
JPM (7)
Kidney cancer (1)
Labor market (3)
Layoffs (60)
Leadership (2)
Legal (412)
Liver cancer (11)
Longevity (2)
Lung cancer (82)
Lymphoma (86)
Machine learning (6)
Management (1)
Manufacturing (109)
MASH (7)
Medical device (319)
Medtech (320)
Mergers & acquisitions (1648)
Metabolic disorders (171)
Multiple sclerosis (12)
NASH (1)
Neurodegenerative disease (74)
Neuropsychiatric disorders (6)
Neuroscience (550)
NextGen: Class of 2026 (765)
Non-profit (707)
Now hiring (5)
Obesity (91)
Opinion (54)
Ovarian cancer (10)
Pain (13)
Pancreatic cancer (27)
Parkinson's disease (64)
Partnered (2)
Patents (46)
Patient recruitment (67)
Peanut (1)
People (7445)
Pharmaceutical (3)
Pharmacy benefit managers (1)
Phase 1 (3848)
Phase 2 (4543)
Phase 3 (3193)
Pipeline (861)
Policy (22)
Postmarket research (214)
Preclinical (1727)
Press Release (19)
Prostate cancer (25)
Psychedelics (3)
Radiopharmaceuticals (17)
Rare diseases (435)
Real estate (522)
Recruiting (4)
Regulatory (3052)
Reports (9)
Research institute (789)
Resumes & cover letters (11)
Rett syndrome (26)
RNA editing (11)
RSV (4)
Schizophrenia (13)
Series A (36)
Series B (34)
Service/supplier (1)
Sickle cell disease (47)
Special edition (4)
Spinal muscular atrophy (139)
Sponsored (6)
Startups (634)
Stomach cancer (1)
Supply chain (7)
Tariffs (2)
The Weekly (7)
Vaccines (100)
Venture capital (12)
Weight loss (32)
Women's health (9)
Date
Last 7 days (93)
Last 30 days (309)
Last 365 days (4679)
2026 (477)
2025 (4749)
2024 (5568)
2023 (5981)
2022 (7993)
2021 (8366)
2020 (6931)
2019 (5670)
2018 (4230)
2017 (4299)
2016 (3838)
2015 (4495)
2014 (3141)
2013 (2475)
2012 (2245)
2011 (2202)
2010 (1921)
Location
Africa (96)
Alabama (4)
Alaska (2)
Arizona (17)
Arkansas (1)
Asia (4057)
Australia (929)
California (1879)
Canada (324)
China (104)
Colorado (67)
Connecticut (54)
Delaware (23)
Europe (11140)
Florida (177)
Georgia (16)
Hawaii (1)
Idaho (4)
Illinois (58)
India (4)
Indiana (166)
Iowa (3)
Japan (87)
Kansas (6)
Kentucky (4)
Louisiana (6)
Maine (4)
Maryland (181)
Massachusetts (1844)
Michigan (76)
Minnesota (44)
Missouri (5)
Montana (2)
Nebraska (4)
Nevada (14)
New Hampshire (3)
New Jersey (296)
New Mexico (4)
New York (459)
North Carolina (241)
North Dakota (5)
Northern California (977)
Ohio (55)
Oklahoma (1)
Oregon (4)
Pennsylvania (333)
Puerto Rico (2)
Rhode Island (7)
South America (122)
South Carolina (3)
Southern California (689)
Tennessee (5)
Texas (249)
United States (6451)
Utah (140)
Virginia (56)
Washington D.C. (11)
Washington State (160)
Wisconsin (12)
84,316 Results for "blueprint genetics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Sanofi Inks $9.5B Blueprint Buyout to Expand Rare Disease Portfolio
Blueprint has a next-generation systemic mastocytosis treatment, called elenestinib, that Sanofi CEO Paul Hudson told analysts provides an “opportunity to grow through the ‘30s.”
June 2, 2025
·
3 min read
·
Nick Paul Taylor
Press Releases
Agendia to Showcase MammaPrint and BluePrint Utility in Guiding Anthracycline Therapy at the 2025 San Antonio Breast Cancer Symposium
November 26, 2025
·
5 min read
Press Releases
Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium
November 5, 2025
·
3 min read
Press Releases
Press Release: Sanofi completes acquisition of Blueprint Medicines
July 18, 2025
·
9 min read
Press Releases
Agendia to Present FLEX Study Data on Impact of BluePrint® at ESMO Breast Cancer 2025
May 6, 2025
·
4 min read
Press Releases
Targeted Genomics Launches Celiac Genetic Testing Services for Texas Physicians
February 2, 2026
·
2 min read
Lone Star Bio
Vitality Blueprint Unveils Performance Bloodwork Platform
Vitality Blueprint, Inc., a leader in human performance science, is proud to introduce its groundbreaking Performance Bloodwork Platform.
April 1, 2024
·
3 min read
Press Releases
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
June 2, 2025
·
21 min read
Immunology and inflammation
Cogent Jumps on Positive Mid-Stage Mastocytosis Data and NDA Plans
A readout from the company’s SUMMIT trial put its small molecule bezuclastinib on a collision course with rival Blueprint’s Ayvakit, which Leerink analysts said does not sufficiently treat all patients.
July 7, 2025
·
1 min read
·
Dan Samorodnitsky
Business
Blueprint’s Cancer Drug Gavreto Finds New Home at Rigel after Roche Split
A year after Roche returned Gavreto’s global rights to Blueprint Medicines, Rigel Pharmaceuticals has acquired the U.S. rights to the FDA-approved treatment for non-small cell lung cancer.
February 23, 2024
·
2 min read
·
Tristan Manalac
1 of 8,432
Next
